EDAN(SZ:300206) Zheng Quan Shi Bao Wang·2026-01-19 10:17Core Viewpoint - The company, Edan Instruments, forecasts a net profit attributable to shareholders of between 284 million to 332 million yuan for 2025, representing a year-on-year growth of 75% to 105% [1] Group 1: Financial Performance - The company expects steady growth in overall operating revenue for 2025, particularly with double-digit growth in international markets, especially in patient monitoring and ultrasound imaging sectors [1] - Non-recurring gains and losses are anticipated to impact net profit by approximately 14 million yuan, mainly from government subsidies, which is a decrease of around 4 million yuan compared to the previous year [1] Group 2: Strategic Initiatives - The company continues to focus on its development strategy of "innovation, platform-based, and internationalization," enhancing its global business layout and service capabilities in overseas markets [1] - Edan Instruments is accelerating new product development and optimizing its marketing system while advancing its overseas manufacturing strategy and localizing operations [2] - The company has made significant progress in collaboration with the Gates Foundation, with the handheld ultrasound device project entering clinical validation and confirmation stages [2] Group 3: Operational Developments - A new facility of 1940 square meters has been added to enhance the company's business layout in North America, which has received comprehensive certifications including MDSAP and California FDB medical device production licenses [2] - The company has been operating in the U.S. market for over 15 years and aims to improve supply chain resilience and overall service capabilities [2] - The second phase of the industrial building is nearing completion, with internal renovations ongoing, and production capacity will be adjusted based on order growth [3]